PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Coloplast A/s

USPTO PatentsView assignee record - 581 granted patents across 61 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).

Explore the portfolio See the ranking
581
Total patents granted
61
CPC technology areas
13.3
Avg claims per patent
-13%
5-year filing velocity

The verdict

Coloplast holds 581 US patents across 61 technology areas, rank #791 of 50,000 tracked assignees.

#791
of 50,000 US assignees by volume
Top 1%
by Innovation Score (64.9/100)
13.3
avg claims per patent
-13%
filing velocity, last 5 yrs

Portfolio overview

Coloplast A/s has been granted 581 US utility patents between 2015 and 2025, placing Coloplast A/s at rank #791 across all assignees tracked by PlainPatent. This portfolio spans 61 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.3 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a Foreign Corporation, Coloplast A/s is one of the broader-portfolio assignees in the PatentsView dataset. By volume, Coloplast sits between Children's Medical Center Corporation (583 patents, rank #787) and The Government Of The United States Of America, As Represented By The Secretary Of The Navy (579 patents, rank #795) - the closest US assignees by grant volume. The composite Innovation Score of 64.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 271 grants, compared with 310 in the 2015–2019 window, a -13% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Coloplast A/s's 13.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 61 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Coloplast A/s against peers pursuing similar technology classes.

Who files at Coloplast's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Coloplast holds 581 patents at rank #791, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Coloplast

By rank, the assignees closest to #791 in granted patent volume.

Leaders in A61F (Filters Implantable INTO Blood Vessels)

Other assignees with the most granted patents in Coloplast's primary technology class.

Coloplast's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

65 Top 1% higher than 99% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). Below this entry. 60–70: 1,537 US assignees (3%). This entry sits in this band. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

20304050607080 20152016201720182019202020212022202320242025 40
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Coloplast A/s patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 73 12.6%
2016 57 9.8%
2017 74 12.7%
2018 61 10.5%
2019 45 7.7%
2020 31 5.3%
2021 35 6.0%
2022 45 7.7%
2023 62 10.7%
2024 58 10.0%
2025 40 6.9%

Which technologies does Coloplast A/s patent most?

Top 15 of 61 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#791

Across all tracked assignees

Innovation Score

64.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Coloplast A/s hold?
Coloplast A/s holds 581 US granted patents filed between 2015 and 2025, spanning 61 technology areas.
What is Coloplast A/s's Innovation Score?
Coloplast A/s has an Innovation Score of 64.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Coloplast A/s focus on?
Coloplast A/s's top technology area is A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS) with 378 patents. The company has filed patents in 61 CPC subclasses total.
Is Coloplast A/s's patent filing rate increasing or decreasing?
Coloplast A/s's recent filing velocity is -13% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Coloplast A/s's patents?
Coloplast A/s's patents average 13.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Coloplast A/s patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Coloplast's 581 grants land it in the top 1% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Coloplast ranks #791 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61F - see who else leads that technology area. A61F leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.